Trading Signals: GILD Stock Price Prediction and Forecast (Fri. Mar. 14, 2014 - Fri. Oct. 27, 2023)(Gilead Sciences)
| GILD latest price $63.1450 (1.91%) ($63.1450 - $63.1800) on Wed. Aug. 10, 2022. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 1.38% (three month average) | RSI | 61 | Latest Price | $63.1450(1.91%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | GILD advances 0.3% a day on average for past five trading days. | Weekly Trend | GILD advances 1% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support GILD advance at 0% a week (0% probability) IBB(58%) SPLV(56%) DIA(53%) IWD(46%) SDY(46%) | Factors Impacting GILD price | GILD will decline at least -0.69% in a week (0% probabilities). VIXM(-17%) UUP(-13%) TBT(-5%) VXX(-3%) SHY(2%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -0.69% (StdDev 1.38%) | Hourly BBV | 2.1 () | Intraday Trend | 0% | | | |
|
5 Day Moving Average | $61.93(1.96%) | 10 Day Moving Average | $61.19(3.19%) | 20 Day Moving Average | $61.22(3.14%) | To recent high | -2.9% | To recent low | 9.6% | Market Cap | $79.184b | | | | Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. Its primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA. |